Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Dec 31, 2019 - AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
Dec 27, 2019 - The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Dec 24, 2019 - FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
Dec 23, 2019 - AstraZeneca's (AZN) antibody drug conjugate candidate, Enhertu gets FDA approval for treating HER2-positive breast cancer in third or later-line setting.
Dec 23, 2019 - The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
Dec 20, 2019 - The stock market rose to record highs again on Friday as part of a much longer and historic expansion in the US economy.
Dec 20, 2019 - Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Dec 19, 2019 - The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.
Dec 19, 2019 - Pentair (PNR) divests Vaki business unit to focus on the residential and commercial pool segments.